Sitagliptin and glipizide monotherapy is safe and effective in patients with type 2 diabetes and end-stage renal disease (ESRD) requiring dialysis, researchers reported online ahead of print in the ...

While both treatment groups exhibited slight increases in HbA1c from week 24 to week 52, the study demonstrated that patients treated with ONGLYZA had a smaller rise per week in HbA1c compared to ...

Moderate-risk patients with diabetes treated with a sulfonylurea appear to be at a higher risk of major adverse cardiovascular events than those who receive a dipeptidyl peptidase-4 (DPP-4) inhibitor, ...

Episodes of low blood sugar were less frequent in patients treated with dapagliflozin added to metformin than in patients treated with glipizide added to metformin In addition to sustained reductions ...

Highest risk seen with glipizide versus other sulfonylureas and DPP4 inhibitors as second-line therapy. (HealthDay News) — For individuals with type 2 diabetes (T2D) and moderate cardiovascular risk ...

April 7, 2006 -- The US Food and Drug Administration (FDA) has approved first-time generic formulations of glipizide 2.5-mg extended-release tablets for the management of type 2 diabetes; zidovudine ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- In a new post-hoc analysis presented for the first time at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions, significantly more ...

Objective: To provide information on the use of oral antidiabetic agents in pregnancy and breast-feeding. Data Sources: Primary articles were identified by a MEDLINE search (1966-March 2007) using the ...

ORLANDO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a 52-week Phase 3b study in adults with type 2 diabetes who had inadequate ...

Investigational Compound Dapagliflozin Added to Metformin Sustained Reductions in Blood Sugar Levels in Adult Patients with Type 2 Diabetes in Two-Year Study Episodes of low blood sugar were less ...